Last updated: 2026-09-16 14:42:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Xenetic Biosciences, Inc. (XBIO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2,22, with a market capitalisation of $10,15M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,90 to $13,93. This page covers its latest market performance, valuation, price trends and company information.
$10,15M | |
$2,75 | |
$1.074,00 | |
$1,90 | |
$4,27 | |
598,51K | |
41,47K | |
-- | |
$13,93 | |
$1,90 | |
-- | |
-- |
Xenetic Biosciences, Inc. (XBIO) is currently trading at $2,22 as of 2026-09-16 14:41:00, down 48,13% ($2,05) from the previous close of $4,27
During today's regular trading session, XBIO has traded between $1,90 and $1.074,00, with a trading volume of 598,51K shares. The current price is near the lower end of today's range.
Over the past seven days, Xenetic Biosciences, Inc. (XBIO) moved from $4,67 to $2,22, representing a decline of 52,57% ($2,46).
The stock traded between $2,19 and $4,90 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 45,70 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 2,6%
XBIO is currently trading at $2,22, placing it 2,6% of the way from its 52-week low of $1,90 to its 52-week high of $13,93. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 2 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Xenetic Biosciences, Inc. (XBIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.